Evidence map›Paper›PMID 40791435›Full record

ArticlebioRxiv : the preprint server for biology2025

The antigen presenting molecule MR1 binds riboflavin catabolites.

Mohamed R Abdelaal, Jieru Deng, Mitchell P McInerney, Emi Ito, Anthony W Purcell, Sho Yamasaki, Jose Villadangos, Hamish E G McWilliam, Nicholas A Gherardin, Jamie Rossjohn and 1 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Mohamed R AbdelaalInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.
Jieru DengDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria 3000, Australia.
Mitchell P McInerneyInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.
Emi ItoDepartment of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, 565-0871, Japan.
Anthony W PurcellInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.
Sho YamasakiDepartment of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, 565-0871, Japan.
Jose VilladangosDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria 3000, Australia.
Hamish E G McWilliamDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria 3000, Australia.
Nicholas A GherardinDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria 3000, Australia.
Jamie RossjohnInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.
Wael AwadInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.

Funding

Investigating the basis of MAIT cell antigen potencyR01AI148407 · NIAID · UNIVERSITY OF MELBOURNE · PI MCCLUSKEY, JAMES · 2020 to 2024
$2.7M
NIAID NIH HHS R01 AI148407
6 · The paper itself

Abstract

Major histocompatibility-complex (MHC) class I-related (MR1) protein presents vitamin B based antigens to Mucosal-Associated Invariant T (MAIT) cells. While microbial riboflavin precursors are well documented MR1 ligands, it is unclear whether host-generated riboflavin catabolites influence MR1-mediated immunity. Here, we report that riboflavin catabolites, including 10-formylmethylflavin (FMF), lumichrome, lumiflavin and alloxazine bind to MR1 with moderate affinity, while riboflavin itself binds weakly. In contrast to the microbial riboflavin antigens which increase MR1 cell surface expression, the riboflavin catabolites moderately reduced cell surface levels of MR1 by stabilizing and retaining MR1 in the endoplasmic reticulum (ER). The riboflavin catabolites appeared to bind to the intracellular MR1 and inhibit MR1 exit from the ER. These riboflavin catabolites also weakly competed with Vit B based Ags for MR1 binding, thereby inhibiting MAIT cell activation. The crystal structures of MR1 complexed with riboflavin, FMF, lumichrome and lumiflavin, show binding of these three-ringed ligands in the A'-pocket of MR1. The crystal structure of MR1-lumichrome revealed that lumichrome formed a covalent "flavin bond" with MR1-Lys43 differing from the typical Schiff-base bond of MR1-Lys43-Ag complexes. Collectively, we identified three ring isoalloxazines that can bind MR1 and downregulate cell surface expression levels, suggesting a potential role in dampening MAIT cell immunity.

Indexed as

antigen presentationflavin bondlumichromeMAIT cellsMR1riboflavin

Identifiers

PMID40791435
PMCPMC12338742

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.